Viatris Dirección

Dirección controles de criterios 1/4

El CEO de Viatris' es Scott Smith, nombrado en Apr 2023, tiene una permanencia de 1.33 años. posee directamente un 0.007% de las acciones de la empresa, con un valor de $960.59K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 3.8 años, respectivamente.

Información clave

Scott Smith

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.007%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Scott Smith (61 yo)

less than a year

Permanencia

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Smith	CEO & Director	less than a year	sin datos	0.0072% $ 987.9k
Theodora Mistras	Chief Financial Officer	less than a year	sin datos	sin datos
Paul Campbell	Chief Accounting Officer	8.9yrs	sin datos	0.013% $ 1.8m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	sin datos	sin datos
Brian Roman	Chief Legal Officer	6.8yrs	sin datos	0.013% $ 1.8m
Andrew Enrietti	Chief People Officer	3.3yrs	sin datos	sin datos
Menassie Taddese	President of Emerging Markets	no data	sin datos	sin datos
Derek Glover	Chief Quality Officer	no data	sin datos	sin datos
Lara Ramsburg	Chief Corporate Affairs Officer	no data	sin datos	sin datos
Jeffrey Nau	President of Viatris Eye Care Division	no data	sin datos	sin datos
Philippe Martin	Chief R&D Officer	less than a year	sin datos	sin datos
Corinne Le Goff	Chief Commercial Officer	no data	sin datos	sin datos

0.7yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VTRS no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Smith	CEO & Director	1.3yrs	sin datos	0.0072% $ 987.9k
JoEllen Dillon	Independent Non-Executive Director	10yrs	US$400.00k	0.0050% $ 680.1k
Wyllie Cornwell	Independent Director	3.4yrs	US$370.00k	0.0052% $ 710.4k
Elisha Finney	Independent Director	1.3yrs	sin datos	0.0016% $ 218.5k
James Kilts	Independent Director	3.4yrs	US$370.00k	0.0099% $ 1.4m
Harry Korman	Independent Non-Executive Director	5.8yrs	US$375.00k	0.0076% $ 1.0m
Melina Higgins	Independent Non-Executive Chairman	11.2yrs	US$445.00k	0.015% $ 2.0m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$18.50m	0.053% $ 7.3m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	14.6yrs	US$450.00k	0.010% $ 1.4m
Rajiv Malik	Director	12.3yrs	US$22.55m	0.12% $ 16.8m
Richard Mark	Independent Non-Executive Director	4.3yrs	US$365.00k	0.0061% $ 836.8k
Leo Groothuis	Independent Director	less than a year	sin datos	0.0019% $ 255.6k

3.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de VTRS se considera experimentada (3.8 años de antigüedad promedio).

Viatris Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

President of Developed Markets recently sold US$3.0m worth of stock

President & Executive Director exercised options and sold US$3.3m worth of stock

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Viatris Inc., Annual General Meeting, Dec 15, 2023

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Recent updates

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Price target decreased to US$12.55

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Viatris stock rises amid potential plans for €3B sale of European OTC assets

Take These Broken Wings And Learn To Fly Again Viatris

Viatris: 5% Dividend Yield Is A Threat For Investors

Independent Non-Executive Director recently sold US$100k worth of stock

Viatris: Products, Profitability And Pipeline - The Keys To Success

Upcoming dividend of US$0.12 per share

Consensus forecasts updated

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris declares $0.12 dividend

Viatris: A Spinoff To Own